148977 - Is the drug holiday over for post-menopausal women taking osteoporosis medications?
- : Online
After participating in this program GPs will gain a better understanding of the duration and effect of osteoporosis. The program aims to ensure that GPs are well equipped to counsel patients on the safety and efficacy of long-term use of osteoporosis pharmacotherapies, and how to discontinue osteoporosis pharmacotherapies to reduce the risk of femoral fractures and minimise ongoing and rebound fracture risk.
Relevance to General Practice
Osteoporosis is often a “silent” disease, remaining undiagnosed until a fracture occurs. Timely diagnosis by GPs and optimal treatment reduces the risk of further fractures by up to 30%, 50% and 70% in patients with non-vertebral, hip and vertebral fractures, respectively. A burden of disease analysis commissioned by Osteoporosis Australia and based on data from the Geelong Osteoporosis Study estimated that in 2012, 4.74 million (66%) of people over the age of 50 in Australia had osteoporosis or osteopenia – low bone density that is often the precursor to osteoporosis. The prevalence of osteoporosis and osteopenia is estimated to rise by 31% (6.2 million) by 2022. This will result in a 30% increase in the annual fracture incidence, from approximately 141,000 fractures in 2012 to approximately 183,000 in 2022. Approximately 70% of minimal trauma fractures occur in women, with incidence increasing with age in both sexes.
- Recall the different modes of action, clinical onset and duration of effect of osteoporosis pharmacotherapies
- Counsel patients on the safety and efficacy of long-term use of osteoporosis pharmacotherapies
- Evaluate the current data regarding discontinuation of osteoporosis therapy
- Review how to discontinue osteoporosis pharmacotherapies to reduce the risk of medication related osteonecrosis of the jaw and atypical femoral fractures